Mayne Pharma Group Limited (MAYNF)
USD 4.25
(3.41%)
USD 4.25
(3.41%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 218.52 Million AUD | 714.24% |
| 2023 | 26.83 Million AUD | -84.23% |
| 2022 | 170.14 Million AUD | -12.63% |
| 2021 | 194.74 Million AUD | -13.49% |
| 2020 | 225.11 Million AUD | -25.3% |
| 2019 | 301.36 Million AUD | 14.64% |
| 2018 | 262.88 Million AUD | -16.52% |
| 2017 | 314.9 Million AUD | 88.25% |
| 2016 | 167.27 Million AUD | 112.03% |
| 2015 | 78.89 Million AUD | 6.64% |
| 2014 | 73.97 Million AUD | 95.6% |
| 2013 | 37.82 Million AUD | 74.0% |
| 2012 | 21.73 Million AUD | -0.78% |
| 2011 | 21.9 Million AUD | 22.27% |
| 2010 | 17.91 Million AUD | 1622.98% |
| 2009 | 1.03 Million AUD | 26.69% |
| 2008 | 820.81 Thousand AUD | 485.83% |
| 2007 | 140.11 Thousand AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 52.89 Million AUD | 21.03% |
| 2024 Q3 | 56.49 Million AUD | -23.98% |
| 2024 Q4 | 56.49 Million AUD | 0.0% |
| 2024 FY | 159.11 Million AUD | 492.87% |
| 2024 Q2 | 74.32 Million AUD | 40.51% |
| 2023 FY | 26.83 Million AUD | -84.23% |
| 2023 Q3 | 37.79 Million AUD | 324.13% |
| 2023 Q1 | 7.53 Million AUD | -84.99% |
| 2023 Q2 | -16.86 Million AUD | -323.94% |
| 2023 Q4 | 43.7 Million AUD | 15.62% |
| 2022 Q3 | 3.26 Million AUD | -94.08% |
| 2022 Q2 | 55.15 Million AUD | 70.75% |
| 2022 FY | 170.14 Million AUD | -12.63% |
| 2022 Q1 | 32.3 Million AUD | -47.59% |
| 2022 Q4 | 50.17 Million AUD | 1435.81% |
| 2021 Q3 | 42.33 Million AUD | -35.25% |
| 2021 Q4 | 61.63 Million AUD | 45.58% |
| 2021 Q1 | 48.65 Million AUD | -30.33% |
| 2021 FY | 194.74 Million AUD | -13.49% |
| 2021 Q2 | 65.38 Million AUD | 34.39% |
| 2020 Q4 | 69.83 Million AUD | 40.27% |
| 2020 FY | 225.11 Million AUD | -25.3% |
| 2020 Q1 | 55.97 Million AUD | -35.25% |
| 2020 Q2 | 71.1 Million AUD | 27.03% |
| 2020 Q3 | 49.78 Million AUD | -29.99% |
| 2019 Q1 | 80.2 Million AUD | -9.86% |
| 2019 FY | 301.36 Million AUD | 14.64% |
| 2019 Q4 | 86.44 Million AUD | 32.53% |
| 2019 Q3 | 65.22 Million AUD | -18.68% |
| 2019 Q2 | 80.2 Million AUD | 0.0% |
| 2018 Q3 | 88.98 Million AUD | 79.79% |
| 2018 Q1 | 49.49 Million AUD | -31.54% |
| 2018 FY | 262.88 Million AUD | -16.52% |
| 2018 Q4 | 88.98 Million AUD | 0.0% |
| 2018 Q2 | 49.49 Million AUD | 0.0% |
| 2017 Q1 | 85.58 Million AUD | 94.59% |
| 2017 FY | 314.9 Million AUD | 88.25% |
| 2017 Q2 | 85.58 Million AUD | 0.0% |
| 2017 Q3 | 72.29 Million AUD | -15.53% |
| 2017 Q4 | 72.29 Million AUD | 0.0% |
| 2016 Q4 | 43.98 Million AUD | 0.0% |
| 2016 Q3 | 43.98 Million AUD | 9.41% |
| 2016 Q2 | 40.2 Million AUD | 0.0% |
| 2016 Q1 | 40.2 Million AUD | 63.91% |
| 2016 FY | 167.27 Million AUD | 112.03% |
| 2015 Q3 | 24.52 Million AUD | 58.56% |
| 2015 Q2 | 15.46 Million AUD | 0.0% |
| 2015 Q4 | 24.52 Million AUD | 0.0% |
| 2015 FY | 78.89 Million AUD | 6.64% |
| 2015 Q1 | 15.46 Million AUD | -18.88% |
| 2014 Q4 | 19.06 Million AUD | 0.0% |
| 2014 Q2 | 18.45 Million AUD | 0.0% |
| 2014 Q3 | 19.06 Million AUD | 3.3% |
| 2014 FY | 73.97 Million AUD | 95.6% |
| 2014 Q1 | 18.45 Million AUD | 37.15% |
| 2013 Q4 | 13.45 Million AUD | 0.0% |
| 2013 Q3 | 13.45 Million AUD | 0.0% |
| 2013 FY | 37.82 Million AUD | 74.0% |
| 2012 FY | 21.73 Million AUD | -0.78% |
| 2011 FY | 21.9 Million AUD | 22.27% |
| 2010 FY | 17.91 Million AUD | 1622.98% |
| 2009 FY | 1.03 Million AUD | 26.69% |
| 2008 FY | 820.81 Thousand AUD | 485.83% |
| 2007 FY | 140.11 Thousand AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 99.37% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 99.363% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | 99.275% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -1844.709% |
| Novartis AG | 34.18 Billion USD | 99.361% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | 70.607% |